semaglutide step 2 FDA has approved a new, higher-dose 7.2 mg weekly injection of #Wegovy (# semaglutide) for long-term weight management in adults with obesity or overweight. 🔹Indication: It is intended as a “step-up” therapy for Key eligibility criteria for STEP

Muscle strength: Physical function: Happy to discuss more if of interest

Yes, burping is a very common and expected side effect during the first 4-8 weeks of GLP-1 therapy as your stomach adjusts to slower gastric emptying

But gastric sleeve may be the better choice if: Your BMI qualifies you for bariatric surgery You want a a more durable tool You have significant obesity-related medical problems You are tired of the recurring cost of GLP-1 drugs You do not want to rely on indefinite injections You have lost and regained weight repeatedly on diets or medication You want a treatment with a stronger long-term track record For many patients with obesity, gastric sleeve is not a last resort. It is simply the most logical long-term treatment

00:21:38 Steve Small: Right, right

For comparative context, researchers may reference Semaglutide, a selective GLP-1 receptor agonist, and Tirzepatide, a dual GIP/GLP-1 receptor agonist, when examining how incremental receptor targeting across this compound class affects metabolic pathway outcomes

Sep 2016;48(7):829-34